---
schema_version: "secwatch.filing_event.v1"
accession: "0001127537-22-000003"
form_type: "8-K"
ticker: "LUNG"
cik: "0001127537"
company_name: "Pulmonx Corp"
filed_at: "2022-02-23T23:59:59+00:00"
generated_at: "2026-06-27T05:17:34.281769+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulmonx Q4 revenue $13.7M (+39% YoY); FY rev $48.4M (+48%); guides FY22 $55-60M

## Summary
- Q4 net loss $13.0M ($0.35/sh) vs $9.3M ($0.27/sh) YoY; FY net loss $48.7M ($1.35/sh) vs $32.2M ($3.16/sh).
- Q4 gross margin 74.8% (vs 72.0% YoY); FY gross margin 73.6% (vs 64.8%); improvement from production efficiencies.
- U.S. treatment centers for Zephyr Valves expanded to 214, a 45% increase since start of 2021.
- FY 2022 revenue guidance $55-60M; Q1 2022 revenue expected $9-10M due to COVID impact.
- Regulatory submission for Zephyr Valve approval in Japan made in December 2021.

## SEC filing metadata
- accession: 0001127537-22-000003
- form_type: 8-K
- ticker: LUNG
- cik: 0001127537
- company_name: Pulmonx Corp
- filed_at: 2022-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1127537/000112753722000003/0001127537-22-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1127537/000112753722000003/lung-20220223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001127537-22-000003
- JSON: https://secwatch.observer/filing/0001127537-22-000003.json
- Plain text: https://secwatch.observer/filing/0001127537-22-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.